-Secondary patent claims are extremely common (more common than chemical compound patent claims), and have a significant effect on the patent-life of drugs -TRIPS does require member countries to adopt patent protection, but these requirements are general and do not mention secondary patents (reference number 21: Harmonization and Its Discontents: A Case Study of TRIPS Implementation in […]

article of November 2013 after the rejection (april 2013) of the patent application of Glivec (Novartis) and the ‘compulsory licensing’ of (Nexavar from Bayer): -a US government lawyer alledges, that it might be about time ‘…for an international legal complaint against India for its disregard of corporate intellectual property…’ -the U.S. Chamber of Commerce ranks India as “…worst among […]